Compare NKE & TAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NKE | TAK |
|---|---|---|
| Founded | 1964 | 1781 |
| Country | United States | Japan |
| Employees | N/A | N/A |
| Industry | Shoe Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 57.9B | 57.6B |
| IPO Year | 1997 | 2007 |
| Metric | NKE | TAK |
|---|---|---|
| Price | $36.55 | $18.13 |
| Analyst Decision | Buy | |
| Analyst Count | 26 | 0 |
| Target Price | ★ $63.44 | N/A |
| AVG Volume (30 Days) | ★ 26.2M | 2.1M |
| Earning Date | 03-31-2026 | 05-13-2026 |
| Dividend Yield | ★ 3.69% | 3.24% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.10 | N/A |
| Revenue | ★ $46,398,000,000.00 | N/A |
| Revenue This Year | $0.91 | $0.16 |
| Revenue Next Year | $0.56 | $1.22 |
| P/E Ratio | ★ $17.78 | $41.25 |
| Revenue Growth | ★ 0.19 | N/A |
| 52 Week Low | $36.85 | $12.99 |
| 52 Week High | $76.97 | $18.90 |
| Indicator | NKE | TAK |
|---|---|---|
| Relative Strength Index (RSI) | 32.37 | 54.56 |
| Support Level | N/A | $17.87 |
| Resistance Level | $45.01 | $18.51 |
| Average True Range (ATR) | 0.82 | 0.20 |
| MACD | -0.16 | -0.04 |
| Stochastic Oscillator | 0.73 | 19.32 |
Nike is the largest athletic footwear and apparel brand in the world. Footwear generates about two-thirds of its sales. Key performance footwear categories include basketball, running, and football (soccer). Its brands include Nike, Jordan (premium athletic footwear and clothing), NikeSkims (women's athleisure), and Converse (casual footwear). Nike sells products worldwide through company-owned stores, franchised stores (including about 5,500 in China), and third-party retailers. The firm also operates e-commerce platforms in more than 40 countries. Nearly all its production is outsourced to contract manufacturers in more than 30 countries. Nike was founded in 1964 and is based in Beaverton, Oregon.
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.5 trillion in fiscal 2025. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with about 50% from the US, 10% from Japan, 25% from Europe, and 15% from Canada.